STOCK TITAN

Eagle Pharmaceuticals, Inc. - $EGRX STOCK NEWS

Welcome to our dedicated page for Eagle Pharmaceuticals news (Ticker: $EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eagle Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eagle Pharmaceuticals's position in the market.

Rhea-AI Summary
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) to release Q3 2023 financial results on November 9, 2023. President and CEO Scott Tarriff and CFO Brian Cahill to host conference call. Webcast available for replay. Dial-in and webcast details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
conferences earnings
-
Rhea-AI Summary
Eagle Pharmaceuticals has been granted a new patent for its pemetrexed formulations, which includes its FDA-approved commercial formulation of PEMFEXY. The patent will expire in 2036 and is expected to strengthen the company's patent portfolio. Sales of PEMFEXY remain strong, with a 24% market share in the commercial pemetrexed market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
none
-
Rhea-AI Summary
Eagle Pharmaceuticals announces that Centers for Medicare & Medicaid Services has established a unique billing code and granted transitional pass-through payment status for Barhemsys injection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
none
Rhea-AI Summary
Eagle Pharmaceuticals announces first prize at ISAP Annual Meeting for pharmacokinetic analysis of remimazolam in pediatric patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
none
-
Rhea-AI Summary
Eagle Pharmaceuticals to participate in Cantor Global Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
conferences
-
Rhea-AI Summary
Eagle Pharmaceuticals announces positive safety and efficacy results for CAL02 in treating severe community-acquired bacterial pneumonia (SCABP). CAL02 could potentially mitigate organ damage, pro-inflammatory responses, and kill pathogens without contributing to antibiotic resistance. CAL02 granted QIDP and Fast Track Designation by FDA, potentially providing 8-10 years of marketing exclusivity. Phase 2 study ongoing with interim report expected in H1 2024. CAL02 protected by U.S. Patent until September 2035.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
conferences
Rhea-AI Summary
Eagle Pharmaceuticals to present at SNACC Annual Meeting on the effects of Byfavo sedative on cognitive function compared to midazolam.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
conferences
-
Rhea-AI Summary
Eagle plans to file a new drug application for EA-114 in 2024, which could optimize dosing regimen for fulvestrant patients and provide personalized treatment. EA-114 may result in improved patient outcomes. Co-administered products have had sales of $7 billion, growing by 27%. Eagle believes EA-114 is eligible for a unique J-code from CMS and potential regulatory exclusivity and patent protection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
none
-
Rhea-AI Summary
Eagle Pharmaceuticals to present at healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
Rhea-AI Summary
Eagle Pharmaceuticals reiterates its guidance for FY 2023, expecting adjusted non-GAAP EBITDA to be $78.0 - $84.0 million and adjusted non-GAAP earnings per share to be $4.40 - $4.70. The company is confident in its business and product pipeline, positioning itself for sustained long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
none
Eagle Pharmaceuticals, Inc.

Nasdaq:EGRX

EGRX Rankings

EGRX Stock Data

44.97M
10.39M
12.02%
87.17%
9.33%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WOODCLIFF LAKE

About EGRX

specialty pharmaceutical company